Trial Outcomes & Findings for Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) (NCT NCT05804045)

NCT ID: NCT05804045

Last Updated: 2026-05-04

Results Overview

Assessed by central read using Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE3

Target enrollment

94 participants

Primary outcome timeframe

Baseline to Week 25

Results posted on

2026-05-04

Participant Flow

Participant milestones

Participant milestones
Measure
Part 1- Placebo, Part 2/Part 3- Pimicotinib(ABSK021)
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 and have option to receive the open-label Pimicotinib(ABSK021) in Part 2 and Part 3. Placebo: capsule Pimicotinib(ABSK021): capsule
Part 1/Part 2/Part 3- Pimicotinib(ABSK021)
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 and continue on the open-label Pimicotinib(ABSK021) in Part 2 and Part 3. Pimicotinib(ABSK021): capsule
Week 1 to Week 24
STARTED
31
63
Week 1 to Week 24
COMPLETED
29
59
Week 1 to Week 24
NOT COMPLETED
2
4
Week 25 to Week 48
STARTED
31
52
Week 25 to Week 48
COMPLETED
11
28
Week 25 to Week 48
NOT COMPLETED
20
24
Week 49 to End of Study
STARTED
11
23
Week 49 to End of Study
COMPLETED
0
0
Week 49 to End of Study
NOT COMPLETED
11
23

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Part 1/Part 2/Part 3- Pimicotinib(ABSK021)
n=63 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 and continue on the open-label Pimicotinib(ABSK021) in Part 2 and Part 3. Pimicotinib(ABSK021): capsule
Part 1- Placebo, Part 2/Part 3- Pimicotinib(ABSK021)
n=31 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 and have option to receive the open-label Pimicotinib(ABSK021) in Part 2 and Part 3. Placebo: capsule Pimicotinib(ABSK021): capsule
Total
n=94 Participants
Total of all reporting groups
Age, Continuous
42.6 years
STANDARD_DEVIATION 14.30 • n=54 Participants
38.3 years
STANDARD_DEVIATION 12.46 • n=60 Participants
41.2 years
STANDARD_DEVIATION 13.79 • n=114 Participants
Sex: Female, Male
Female
45 Participants
n=54 Participants
19 Participants
n=60 Participants
64 Participants
n=114 Participants
Sex: Female, Male
Male
18 Participants
n=54 Participants
12 Participants
n=60 Participants
30 Participants
n=114 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=54 Participants
0 Participants
n=60 Participants
0 Participants
n=114 Participants
Race (NIH/OMB)
Asian
32 Participants
n=54 Participants
16 Participants
n=60 Participants
48 Participants
n=114 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=54 Participants
0 Participants
n=60 Participants
0 Participants
n=114 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=54 Participants
2 Participants
n=60 Participants
5 Participants
n=114 Participants
Race (NIH/OMB)
White
26 Participants
n=54 Participants
11 Participants
n=60 Participants
37 Participants
n=114 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=54 Participants
0 Participants
n=60 Participants
1 Participants
n=114 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=54 Participants
2 Participants
n=60 Participants
3 Participants
n=114 Participants
Region of Enrollment
Canada
6 participants
n=54 Participants
4 participants
n=60 Participants
10 participants
n=114 Participants
Region of Enrollment
Netherlands
5 participants
n=54 Participants
5 participants
n=60 Participants
10 participants
n=114 Participants
Region of Enrollment
United States
8 participants
n=54 Participants
3 participants
n=60 Participants
11 participants
n=114 Participants
Region of Enrollment
China
31 participants
n=54 Participants
14 participants
n=60 Participants
45 participants
n=114 Participants
Region of Enrollment
Poland
2 participants
n=54 Participants
0 participants
n=60 Participants
2 participants
n=114 Participants
Region of Enrollment
Italy
4 participants
n=54 Participants
2 participants
n=60 Participants
6 participants
n=114 Participants
Region of Enrollment
Spain
7 participants
n=54 Participants
3 participants
n=60 Participants
10 participants
n=114 Participants

PRIMARY outcome

Timeframe: Baseline to Week 25

Assessed by central read using Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)

Outcome measures

Outcome measures
Measure
Part 1- Pimicotinib(ABSK021)
n=63 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=31 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
Objective Response Rate (ORR)
54.0 Percentage of participants
Interval 40.9 to 66.6
3.2 Percentage of participants
Interval 0.1 to 16.7

SECONDARY outcome

Timeframe: Baseline to Week 25

Population: The ITT Set consisted of participants who were randomized to a study treatment regimen.

TVS is a semi-quantitative magnetic resonance imaging (MRI) scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. ORR was the percentage of participants who achieved either Complete Response (CR) or Partial Response (PR) as assessed by Blinded Independent Review Committee using TVS.

Outcome measures

Outcome measures
Measure
Part 1- Pimicotinib(ABSK021)
n=63 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=31 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
Objective Response Rate (ORR) Per Tumor Volumn Score (TVS)
61.9 Percentage of participants
Interval 48.8 to 73.9
3.2 Percentage of participants
Interval 0.1 to 16.7

SECONDARY outcome

Timeframe: Baseline to Week 25

Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.

Presented here is the change from baseline in ROM to Week 25. Measurement of the affected and contralateral, non-affected joint was assessed by goniometer and measured in degrees. At baseline, the motion with the smallest relative ROM value (worst) was identified, and this motion was used for evaluating the change in relative ROM subsequently. The affected joint measurement was used to derive a relative ROM based on the measurement relative to reference standard value provided by the American Medical Association. Relative ROM is expressed in percent: 100 x (joint ROM measure)/(reference ROM standard).

Outcome measures

Outcome measures
Measure
Part 1- Pimicotinib(ABSK021)
n=55 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=28 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
Change From Baseline in Active Range of Motion (ROM) at Week 25
15.64 Percent of range of motion
Interval 10.37 to 20.91
-0.07 Percent of range of motion
Interval -7.02 to 6.88

SECONDARY outcome

Timeframe: Baseline to Week 25

Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.

The Worst Stiffness NRS is a single question that asks the participant to assess their worst stiffness in the last 24 hours. Participants rate their worst stiffness on a scale of 0 to 10, where 0 is "no stiffness" and 10 is "worst imaginable." Lower scores represented better level of stiffness.

Outcome measures

Outcome measures
Measure
Part 1- Pimicotinib(ABSK021)
n=56 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=29 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
Change From Baseline in the Worst Stiffness Numeric Rating Scale (NRS) Score at Week 25
-3.00 score on a scale
Interval -3.46 to -2.55
-0.57 score on a scale
Interval -1.21 to 0.07

SECONDARY outcome

Timeframe: Baseline to Week 25

Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.

Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is "no pain" and 10 is "pain as bad as you can imagine."

Outcome measures

Outcome measures
Measure
Part 1- Pimicotinib(ABSK021)
n=56 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=29 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
Change From Baseline in Brief Pain Inventory (BPI) Worst Pain NRS Score at Week 25
-2.32 Score on a scale
Interval -2.73 to -1.91
-0.23 Score on a scale
Interval -0.8 to 0.34

SECONDARY outcome

Timeframe: Baseline to Week 25

Population: The analyzed population in the modeling of continuous endpoints would include all ITT participants who had both baseline and post-baseline available data.

All participants were asked 11 or 13 questions from the PROMIS-PF item bank. The questions used one of two 5-point verbal rating scales: either 1 = "unable to do", 2 = "with much difficulty", 3 = "with some difficulty", 4 = "with a little difficulty", and 5 = "without any difficulty"; or 1 = "cannot do", 2 = "quite a lot", 3 = "somewhat", 4 = "very little", and 5 = "not at all." The T-score rescales the total raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean. The T-score ranges from 0 to 100, with a higher score indicating better physical function status.

Outcome measures

Outcome measures
Measure
Part 1- Pimicotinib(ABSK021)
n=56 Participants
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1 Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=29 Participants
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1 Placebo: capsule
Change From Baseline in the Patient-reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 25
5.63 T-score
Interval 4.21 to 7.06
2.23 T-score
Interval 0.23 to 4.24

Adverse Events

Part 1 Pimicotinib(ABSK021)

Serious events: 3 serious events
Other events: 62 other events
Deaths: 0 deaths

Part 1- Placebo

Serious events: 1 serious events
Other events: 27 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Part 1 Pimicotinib(ABSK021)
n=63 participants at risk
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1. Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=31 participants at risk
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1. Placebo: capsule
Infections and infestations
Enterocolitis infectious
1.6%
1/63 • Number of events 1 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Blood pressure increased
1.6%
1/63 • Number of events 1 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Skin and subcutaneous tissue disorders
Erythema nodosum
1.6%
1/63 • Number of events 1 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
0.00%
0/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)

Other adverse events

Other adverse events
Measure
Part 1 Pimicotinib(ABSK021)
n=63 participants at risk
Participants receive the blinded treatment of ABSK021 for 24 weeks in Part 1. Pimicotinib(ABSK021): capsule
Part 1- Placebo
n=31 participants at risk
Participants receive the blinded treatment of matching placebo for 24 weeks in Part 1. Placebo: capsule
Investigations
Alpha hydroxybutyrate dehydrogenase increased
25.4%
16/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Lipase increased
23.8%
15/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Blood creatine phosphokinase MB (Myocardial Band) increased
19.0%
12/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Blood creatine phosphokinase increased
71.4%
45/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
16.1%
5/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Blood lactate dehydrogenase increased
57.1%
36/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Aspartate aminotransferase increased
54.0%
34/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Amylase increased
34.9%
22/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
General disorders
Face oedema
47.6%
30/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
General disorders
Fatigue
28.6%
18/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
22.6%
7/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
General disorders
Oedema peripheral
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
General disorders
Pyrexia
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
General disorders
Asthenia
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
General disorders
Generalised oedema
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
General disorders
Influenza like illness
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Alanine aminotransferase increased
17.5%
11/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
High density lipoprotein increased
15.9%
10/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Blood creatinine increased
15.9%
10/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
White blood cell count decreased
12.7%
8/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Apolipoprotein A-I increased
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Blood cholesterol increased
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Neutrophil count decreased
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Apolipoprotein B decreased
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Blood alkaline phosphatase increased
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Low density lipoprotein increased
3.2%
2/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Urinary occult blood positive
1.6%
1/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Investigations
Urobilinogen urine increased
1.6%
1/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Skin and subcutaneous tissue disorders
Pruritus
52.4%
33/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Skin and subcutaneous tissue disorders
Rash
34.9%
22/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Skin and subcutaneous tissue disorders
Rash maculo-papular
11.1%
7/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Skin and subcutaneous tissue disorders
Dermatitis acneiform
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Eye disorders
Periorbital oedema
31.7%
20/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Eye disorders
Eyelid oedema
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Gastrointestinal disorders
Nausea
27.0%
17/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Gastrointestinal disorders
Diarrhoea
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Gastrointestinal disorders
Vomiting
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Gastrointestinal disorders
Mouth ulceration
1.6%
1/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Nervous system disorders
Headache
20.6%
13/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Nervous system disorders
Dizziness
15.9%
10/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Metabolism and nutrition disorders
Hypercholesterolaemia
14.3%
9/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Metabolism and nutrition disorders
Decreased appetite
9.5%
6/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Metabolism and nutrition disorders
Hypertriglyceridaemia
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Infections and infestations
Upper respiratory tract infection
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Infections and infestations
Urinary tract infection
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Infections and infestations
Influenza
4.8%
3/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
9.7%
3/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Musculoskeletal and connective tissue disorders
Arthralgia
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
22.6%
7/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Musculoskeletal and connective tissue disorders
Myalgia
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Musculoskeletal and connective tissue disorders
Pain in extremity
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Psychiatric disorders
Insomnia
14.3%
9/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Vascular disorders
Hypertension
14.3%
9/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Respiratory, thoracic and mediastinal disorders
Cough
7.9%
5/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Renal and urinary disorders
Haematuria
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Cardiac disorders
Palpitations
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
3.2%
1/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Cardiac disorders
Sinus bradycardia
0.00%
0/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Blood and lymphatic system disorders
Anaemia
6.3%
4/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
0.00%
0/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
Reproductive system and breast disorders
Heavy menstrual bleeding
0.00%
0/63 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)
6.5%
2/31 • Collection of adverse events started from the signing of informed consent through safety follow-up (up to 5.9 months)

Additional Information

Dr Yi Liu, Senior Medical Director

Abbisko Therapeutics Co, Ltd

Phone: +86-21-68910052

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place